Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson CEO Bisaro Ordered To Comply With FTC Subpoena

This article was originally published in The Pink Sheet Daily

Executive Summary

Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.

You may also be interested in...

Cephalon Loses Market Exclusivity On Provigil To Its Own Parent Company

Teva’s March 30 authorized generic launch appears to give it a jump over other modafinil ANDA holders, who had settled patent litigation with Cephalon and were expected to enter the market in April. Several companies are expected to share 180-day marketing exclusivity rights for modafinil, although the fate of Ranbaxy’s ANDA under a recently negotiated FDA consent decree remains unclear.

FTC Can Enforce Subpoena Against Watson CEO Bisaro

A D.C. magistrate judge grants FTC's request to enforce a subpoena against Bisaro and finds the agency did not share Watson's confidential information with Apotex.

Watson CEO Claims FTC Pressured Company To Allow Apotex To Market Generic Provigil

Watson CEO Paul Bisaro is fighting an FTC subpoena to testify in the commission's investigation of a reverse settlement agreement involving Cephalon's Provigil.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts